Combating subclonal evolution of resistant cancer phenotypes

Combating subclonal evolution of resistant cancer phenotypes

In metastatic breast cancer, subclonal evolution can drive drug resistance. Here, the authors genetically and transcriptionally follow the evolution of four breast cancers over time and treatment, and suggest a phenotype-targeted treatment strategy to adapt to cancer as it evolves.

Manylion Llyfryddiaeth
Prif Awduron: Samuel W. Brady, Jasmine A. McQuerry, Yi Qiao, Stephen R. Piccolo, Gajendra Shrestha, David F. Jenkins, Ryan M. Layer, Brent S. Pedersen, Ryan H. Miller, Amanda Esch, Sara R. Selitsky, Joel S. Parker, Layla A. Anderson, Brian K. Dalley, Rachel E. Factor, Chakravarthy B. Reddy, Jonathan P. Boltax, Dean Y. Li, Philip J. Moos, Joe W. Gray, Laura M. Heiser, Saundra S. Buys, Adam L. Cohen, W. Evan Johnson, Aaron R. Quinlan, Gabor Marth, Theresa L. Werner, Andrea H. Bild
Fformat: Erthygl
Iaith:English
Cyhoeddwyd: Nature Portfolio 2017-11-01
Cyfres:Nature Communications
Mynediad Ar-lein:https://doi.org/10.1038/s41467-017-01174-3

Rhyngrwyd

https://doi.org/10.1038/s41467-017-01174-3

Eitemau Tebyg